Oncology development
Rasonque’s $197.6M Launch and the Next Pancreatic Cancer Trials
Review Rasonque’s $197.6M launch, the RASolute 302 survival results and what the first-line RASolute 303 and 309 studies will ask of oncology sites.
By Lampgen Clinical Research
· Updated

4 min read · estimated
What the source reported
Rasonque’s early U.S. launch shows strong uptake in metastatic pancreatic cancer. The next clinical question is whether daraxonrasib can improve outcomes earlier in the disease course for patients eligible for first-line combination chemotherapy. Two randomized Phase 3 trials are testing different ways to answer that question. [1, 2]
Revolution Medicines reported $197.6 million in Rasonque net product revenue and more than 5,000 unique U.S. patients receiving the commercial drug through September 30, 2026, after roughly five weeks on the market. Initial stocking contributed to revenue. Expanded-access transitions and patients already waiting for a new option contributed to early treatment starts. As those effects recede, newly eligible starts and treatment duration will help explain ongoing uptake. [1–3]
The FDA approved daraxonrasib on August 26 for adults with metastatic pancreatic adenocarcinoma who had received prior systemic treatment or for whom multiagent systemic therapy is unsuitable. Daraxonrasib is an oral inhibitor that targets multiple forms of active RAS, a driver of pancreatic cancer growth. In the open-label RASolute 302 trial, 500 previously treated patients were randomized to daraxonrasib or investigator-selected chemotherapy. Median overall survival across the full trial population was 13.2 versus 6.7 months (hazard ratio 0.40, 95% CI 0.30–0.53). Median progression-free survival was 7.2 versus 3.6 months. Median follow-up at the February 10, 2026, analysis cutoff was 8.5 months. [4, 5, 10]
The survival result comes with a distinct tolerability profile. Grade 3 or higher adverse events after treatment began occurred in 61.8% of the daraxonrasib group and 69.6% of the chemotherapy group. The FDA label includes warnings for skin and soft-tissue toxicity, oral disorders, diarrhea, gastrointestinal perforation and pneumonitis, among others. The randomized evidence comes from previously treated patients. First-line monotherapy and combinations in patients eligible for multiagent chemotherapy require their own efficacy and safety evidence. [4–6]
The international access timeline is separate. On October 15, the European Medicines Agency’s human medicines committee recommended authorization for previously treated adults. An authorization decision rests with the European Commission, with country-specific pricing and reimbursement processes to follow any authorization. [7]
What this means for trial teams
Two Phase 3 trials ask different first-line questions. RASolute 303 compares daraxonrasib alone and daraxonrasib plus gemcitabine and nab-paclitaxel with gemcitabine and nab-paclitaxel. In its November 4 update, Revolution Medicines reported that U.S. enrollment was complete and projected global enrollment would finish in the first half of 2027. RASolute 309 compares daraxonrasib plus investigational zoldonrasib with the same chemotherapy backbone in patients with a documented KRAS G12D mutation. Both designs assess overall and progression-free survival. [2, 8, 9]
Measure where screening time is lost. In a mutation-selected trial like RASolute 309, track time from referral to a usable KRAS G12D result. Separate tissue retrieval, test turnaround and eligibility review. Record how often patients need to start treatment before screening finishes. Reviewing those intervals across referral networks and community and academic sites can show where logistics narrow access to trial participation.
Reconcile each drug’s dose history. When a participant develops diarrhea or mouth sores on a combination regimen, the investigator’s assessment and the action taken for each drug should be traceable. Monitors can reconcile symptom onset, severity, holds, reductions and restarts across clinic notes, pharmacy records and the electronic case report form. Repeat gaps across sites give the study team a reason to check whether its documentation and escalation instructions are clear.
Follow patients after treatment changes. If patients discontinue study therapy or receive subsequent treatment, collect survival follow-up and subsequent therapy data as the protocol allows. For the commercial launch, measure time from prescription to dispensing and reasons for delayed starts across payer and practice settings. These are different workflows with the same practical need for an owner at every handoff.
For sponsors and CROs, turn those responsibilities into a staffing brief. Ask oncology CRA candidates how they would investigate an incomplete dose-hold timeline, route a safety finding and verify that the site’s correction worked. Lampgen Clinical Research matches oncology monitoring experience to the study work the CRA will own.
Sources
- 1. Revolution Medicines Q3 2026 Form 10-Q
- 2. Revolution Medicines Q3 2026 results and program updates
- 3. Fierce Pharma reporting on launch drivers, November 5, 2026
- 4. FDA approval notice and RASolute 302 results
- 5. O’Reilly et al., RASolute 302, New England Journal of Medicine
- 6. FDA Rasonque prescribing information
- 7. European Medicines Agency Rasonque assessment
- 8. ClinicalTrials.gov RASolute 303 (NCT07491445)
- 9. National Cancer Institute RASolute 309 (NCT07805954)
- 10. ASCO RASolute 302 primary analysis, including data cutoff and follow-up